A good laugh

Quote

Anonymous

Guest
Have any of you checked out the yahoo stock board? It is hilarious. Don't you wish you could take a couple of those "yahoos" with you on a few doctor calls to see the real world?
 






PULSE: KV Pharmaceutical tumbles after business update


BOSTON (MarketWatch) -- Shares of KV Pharmaceuticals KV.AKV.B tumbled nearly 20% in afternoon trading Tuesday, the day after the company filed its 10-K report with securities regulators. Late Monday, KV also held a conference call with investors to various company matters.
 






The markets were less than impressed with sales of Makena at KV Pharmaceutical. The drugmaker created a firestorm of indignation earlier this year, when it announced a pricing scheme for the drug that made it look as if it was trying to profiteer off at-risk babies.

To quell the uproar, KV first offered financial assistance to those who couldn't afford the $1,500-per-dose cost (um, "everyone"?), and then when that feeble attempt failed, it cut the price to $690. The FDA then weighed in and said it wouldn't grant Makena exclusivity, meaning the original lower-cost options would still be available. The PR disaster was reflected in KV's quarterly results.

Since March 31, it has shipped only 200 vials of Makena, and although 1,700 patients have been referred to the enrollment and treatment, almost half (800) failed to get a Makena prescription filled. Revenues for the quarter came in at just $16.8 million, well below the $36 million Wall Street was expecting, and more ominously, a going-concern notice was included in the annual report, meaning its auditors question whether it can survive.
 






Anonymous said:
The markets were less than impressed with sales of Makena at KV Pharmaceutical. The drugmaker created a firestorm of indignation earlier this year, when it announced a pricing scheme for the drug that made it look as if it was trying to profiteer off at-risk babies.

To quell the uproar, KV first offered financial assistance to those who couldn't afford the $1,500-per-dose cost (um, "everyone"?), and then when that feeble attempt failed, it cut the price to $690. The FDA then weighed in and said it wouldn't grant Makena exclusivity, meaning the original lower-cost options would still be available. The PR disaster was reflected in KV's quarterly results.

Since March 31, it has shipped only 200 vials of Makena, and although 1,700 patients have been referred to the enrollment and treatment, almost half (800) failed to get a Makena prescription filled. Revenues for the quarter came in at just $16.8 million, well below the $36 million Wall Street was expecting, and more ominously, a going-concern notice was included in the annual report, meaning its auditors question whether it can survive.
Click to expand...

Duh! Of course it can't survive - it has $400 million of debt, owes Hologic another $100 million, has virtually no sales, is loss-making and now has a competitor (Prochieve) about to be launched in the hands of a much more solvent, credible and competent competitor (Watson).

R-I-P
 












Top Bottom
Back
Quote